Q2 2024 13F Holders as of 30 Jun 2024
-
Type / Class
-
Equity / COM
-
Number of holders
-
10
-
Total 13F shares, excl. options
-
7,025,014
-
Shares change
-
-60,693,049
-
Total reported value, excl. options
-
$98,771,327
-
Value change
-
-$1,024,949,936
-
Number of buys
-
3
-
Number of sells
-
-110
-
Price
-
$14.06
Significant Holders of AVADEL PHARMACEUTICALS - COM (AVDL) as of Q2 2024
129 filings reported holding AVDL - AVADEL PHARMACEUTICALS - COM as of Q2 2024.
AVADEL PHARMACEUTICALS - COM (AVDL) has 10 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 7,025,014 shares
.
Largest 10 shareholders include Vivo Capital, LLC (3,972,099 shares), Tri Locum Partners LP (1,189,518 shares), MPM BIOIMPACT LLC (783,242 shares), Knoll Capital Management, LLC (600,000 shares), Knott David M Jr (333,000 shares), SCHULHOFF & CO INC (137,000 shares), Ameritas Investment Partners, Inc. (9,055 shares), 1620 INVESTMENT ADVISORS, INC. (1,000 shares), CWM, LLC (99 shares), and HUNTINGTON NATIONAL BANK (1 shares).
This table shows the top 10 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.